This company has been marked as potentially delisted and may not be actively trading. Akers Biosciences (AKER) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock AKER vs. MYMD, NAVB, VNRX, ARTL, CDIO, PMCB, AEZS, NLSP, ALZN, and SBFMShould you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), VolitionRx (VNRX), Artelo Biosciences (ARTL), Cardio Diagnostics (CDIO), Nuvilex (PMCB), Aeterna Zentaris (AEZS), NLS Pharmaceutics (NLSP), Alzamend Neuro (ALZN), and Sunshine Biopharma (SBFM). These companies are all part of the "medical" sector. Akers Biosciences vs. Its Competitors MyMD Pharmaceuticals Navidea Biopharmaceuticals VolitionRx Artelo Biosciences Cardio Diagnostics Nuvilex Aeterna Zentaris NLS Pharmaceutics Alzamend Neuro Sunshine Biopharma MyMD Pharmaceuticals (NASDAQ:MYMD) and Akers Biosciences (NASDAQ:AKER) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk. Which has more volatility & risk, MYMD or AKER? MyMD Pharmaceuticals has a beta of 2.15, suggesting that its stock price is 115% more volatile than the S&P 500. Comparatively, Akers Biosciences has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Is MYMD or AKER more profitable? Akers Biosciences' return on equity of -87.42% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MyMD PharmaceuticalsN/A -179.05% -108.14% Akers Biosciences N/A -87.42%-73.31% Does the media favor MYMD or AKER? In the previous week, MyMD Pharmaceuticals' average media sentiment score of 0.00 equaled Akers Biosciences'average media sentiment score. Company Overall Sentiment MyMD Pharmaceuticals Neutral Akers Biosciences Neutral Do insiders & institutionals believe in MYMD or AKER? 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. Comparatively, 5.5% of Akers Biosciences shares are held by institutional investors. 2.1% of MyMD Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Akers Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, MYMD or AKER? Akers Biosciences has higher revenue and earnings than MyMD Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyMD PharmaceuticalsN/AN/A-$4MN/AN/AAkers Biosciences$1.58M1.02-$3.89MN/AN/A SummaryAkers Biosciences beats MyMD Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Akers Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKER vs. The Competition Export to ExcelMetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61M$17.06M$5.50B$9.72BDividend YieldN/AN/A4.59%4.12%P/E RatioN/AN/A30.0524.70Price / Sales1.0219.16456.53100.55Price / CashN/AN/A24.8428.01Price / Book0.020.018.525.76Net Income-$3.89M-$15.34M$3.27B$267.05M Akers Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKERAkers BiosciencesN/A$0.10-1.6%N/A-94.6%$1.61M$1.58M0.004High Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.11+5.7%N/A-94.6%$253KN/A0.006Gap UpHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$50K$8.13K0.0010VNRXVolitionRx2.4506 of 5 stars$0.64+2.7%$3.50+446.9%+21.4%$66.55M$1.31M-1.7880News CoverageGap UpARTLArtelo Biosciences2.4129 of 5 stars$9.48-4.5%$24.00+153.2%+9.6%$6.99MN/A-0.535News CoverageUpcoming EarningsAnalyst DowngradeShort Interest ↑Gap DownCDIOCardio Diagnostics2.5692 of 5 stars$3.98-0.3%$60.00+1,407.5%-74.0%$6.95M$40K0.001News CoveragePositive NewsUpcoming EarningsGap UpPMCBNuvilex1.4391 of 5 stars$1.02+1.6%N/A-55.1%$6.86MN/A1.374Positive NewsUpcoming EarningsGap DownAEZSAeterna ZentarisN/A$3.82-2.1%N/A-37.2%$6.85M$2.37M-0.2620Upcoming EarningsGap UpNLSPNLS PharmaceuticsN/A$1.90+0.7%N/A+1,013.4%$6.79MN/A0.006Positive NewsUpcoming EarningsAnalyst UpgradeALZNAlzamend Neuro2.7561 of 5 stars$2.38+2.6%$180.00+7,463.0%-87.7%$6.72MN/A0.004News CoverageAnalyst DowngradeSBFMSunshine Biopharma1.595 of 5 stars$1.43-2.1%$15.00+949.0%-49.5%$6.65M$34.87M-0.013Upcoming Earnings Related Companies and Tools Related Companies MyMD Pharmaceuticals Alternatives Navidea Biopharmaceuticals Alternatives VolitionRx Alternatives Artelo Biosciences Alternatives Cardio Diagnostics Alternatives Nuvilex Alternatives Aeterna Zentaris Alternatives NLS Pharmaceutics Alternatives Alzamend Neuro Alternatives Sunshine Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKER) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
